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We examined the usefulness of brief neuropsychological tests and serum Aβ as a predictive test for detecting MCI/AD in older
adults. Serum Aβ levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw. Twenty-
eight of the subjects subsequently developed MCI (n = 18) or AD (n = 10) over the follow-up period. Baseline measures of
global cognition, memory, language ﬂuency, and serum Aβ1−42 and the ratio of serum Aβ1−42/Aβ1−40 were signiﬁcant predictors
for future MCI/AD using Cox regression with demographic variables, APOE ε4, vascular risk factors, and speciﬁc medication as
covariates.An optimalsensitivityof85.2%andspeciﬁcity of86.5%forpredicting MCI/ADwasachieved usingROCanalyses.Brief
neuropsychological tests and measurements of Aβ1−42 obtained via blood warrants further study as a practical and cost eﬀective
method for wide-scale screening for identifying older adults who may be at-risk for pathological cognitive decline.
1.Introduction
An exponential rise in Alzheimer’s disease (AD) prevalence
rates is predicted to parallel the aging of baby boomers
creating a potentially unsustainable economic burden to the
healthcare system. Delaying the onset or progression of AD,
evenmodestly,byearlierpharmacologicalinterventioncould
substantially reduce the economic and psychosocial impact
of the illness [1, 2]. Unfortunately, many AD patients remain
undiagnosed or go undetected until the later stages of dis-
ease. Insights into the underlying pathological mechanisms
involving beta-amyloid plaque deposition within the brain
have led to the development of a host of antiamyloid agents
[3] that are invarious stagesofclinical investigation. There is
now a scientiﬁc consensus that the pathological eventsin AD
initiate decades before clinical symptoms become apparent,
and if disease modiﬁcation is realized in the coming decades,
the need for improved methods of early detection prior to
the overt clinical signs will be accentuated.
Traditionally, neuropsychological measures, particularly
those that tap cognitive abilities subsumed by the hip-
pocampal formation such as episodic memory, have shown
usefulness in identifying cognitively normal elders who
subsequently develop AD [4, 5]. Decrements in semantic
memory and concept formation have been shown to occur
nearly a decade before the development of AD [6]. Per-
formance on visual-spatial and verbal memory measures
in midlife have also been shown to predict later memory
loss [7]. Neuropsychological measures are noninvasive and
generally cost eﬀective. However, individuals with very
high premorbid intellectual abilities experiencing incipient
cognitive decline may go undetected, and false positives are
possibleinindividualswithalowlevelofintellectualabilities.
Alsoappropriateinterpretationofextensiveneuropsycholog-
ical testing requires a high degree of expertise and training,
which limits its use in routine clinical settings.
The advancement of molecular imaging tracers that bind
toamyloid, suchasPittsburghCompoundB(PIB)orlonger-
lived probes (e.g., FDDNP), oﬀers a non-invasive in vivo
method to detect and quantify brain amyloid deposition
[8, 9]. However, this approach for presymptomatic detection
is economically impractical for routine use given the current
costsandrestrictions on“medicallynecessary” use.Similarly,
biomarkers including Aβ1−42 and phosphorylated tau (also2 International Journal of Alzheimer’s Disease
implicated in AD pathology) in cerebral spinal ﬂuid (CSF)
canpredictsubsequentcognitivedecline[10,11],butlumbar
puncture carries risks and is inconvenient for wide-scale use
in cognitively impaired elderly subjects.
Blood-based biomarkers have more practical applicabil-
ity for routine use and are likely to be more cost eﬀective
than both CSF and imaging procedures. Consequently,
measurement of Aβ1−40 and Aβ1−42 in blood is increasingly
beingexploredandshowspotentialinidentifyingindividuals
at the preclinical stage of AD [12–14]. It has been reported
that CSF Aβ levels are subject to high diurnal ﬂuctuations
with extremely high variability reported over 12 hours [15].
Over days and weeks, Aβ in blood appears more stable than
CSF [16–18]. Furthermore, serum contains more Aβ than
plasma [16], possibly due to the release of bound Aβ during
the clotting process [19]. Hence, serum Aβ appears suitable
for use in predicting MCI/AD and optimal sensitivity, and
speciﬁcity is probably achievable if combined with current
diagnostic procedures, such as brief neuropsychological
testing.
In this study, we examined the usefulness of brief
neuropsychological tests in combination with blood Aβ1−40
and Aβ1−42 as a predictive test for detecting MCI/AD in
at-risk older adults at a pre-symptomatic stage. Such an
approach will be more practical for clinical use and be
germane in designing large-scale prevention trials.
2.Methods
2.1. Subjects. Participants included a subset of subjects
enrolled in the Alzheimer’s Disease Anti-Inﬂammatory
Prevention Trial (ADAPT). ADAPT was a randomized,
placebo-controlled, multicenter primary prevention trial
sponsored by the National Institute on Aging. The Roskamp
Institute served as one of six recruitment sites located
across the US. Subjects were randomly assigned to one of
three groups: celecoxib (200mg b.i.d.), naproxen sodium
(220mg b.i.d.), or placebo. The primary outcome measure
of ADAPT was development of AD. Full details of data
collection,measurements, andstudyproceduresare available
athttp://www.jhucct.com/adapt/manall43.pdfand described
elsewhere [20].
The inclusion criteria for ADAPT subjects were age of 70
or older at enrollment, a self-reported family history of AD-
like dementia, and normal cognitive performance on a brief
battery of neuropsychological tests. Recruitment for ADAPT
began in2002,and thestudy wascompletedin 2007.In2005,
the Roskamp Institute initiated a proteomic ancillary study
(F. Crawford, PI) involving blood draw from these subjects.
The inclusion criteria for this ancillary study stipulated that
each subject was an active ADAPT participant and had met
all the ADAPT inclusion and exclusion criteria. An approval
was obtained from the ADAPT Steering Committee and a
centralized IRB. A separate consent was also obtained from
each subject who participated in the ancillary study.
Two hundred and ﬁfteen subjects from the Roskamp
ADAPT cohort enrolled in the proteomic ancillary study. At
the time of blood draw, subjects maintained cognitively nor-
mal status as determined by their performance on an annual
cognitive assessment battery. These assessments continued
for an additional two years following the blood draw. Blood
wascollectedduring thesemi-annual followupvisits, and the
cognitive assessments were performed at the baseline visit
and at the annual visits. The time from baseline cognitive
testing tothe diagnosis of MCI/ADwas 4.06years (±1.3SD).
Timeframe from baseline cognitivetesting toblooddraw was
2.25 years (±0.71 SD)and from blood draw to diagnosis was
1.79 years (±1.2 SD). The cognitive measures completed at
baseline and annual followup included the Modiﬁed Mini-
Mental State Examination (3MS) [21]; the Hopkins Verbal
Learning Test-Revised (HVLT-R) [22]; Digit Span (forward
and backward) from the Wechsler Adult Intelligence Scale-
Revised (WAIS-R) [23]; a Generative Verbal Fluency test
(supermarket items); the narratives from the Rivermead
BehavioralMemoryTest(RBMT)[24];theBriefVisuospatial
Memory Test-Revised (BVMT-R) [25]. The Mini-Mental
State Examination (MMSE) [26] was extracted from 3MS.
Alternate forms were utilized annually for the HVLT-R,
RBMT, and BVMT-R on each subsequent annual visit.
Subjects also completed the 30-item Geriatric Depression
Scale [27] and a self-rating scale of memory functions [28].
Collateral respondents completed the Dementia Severity
Rating Scale (DSRS) [29]. Due to signiﬁcant intercorre-
lations between these tests, analyses described below are
limited to those baseline cognitive tests that were sensitive to
early changes (i.e., verbal learning and memory) associated
with MCI/AD [30] or tests that were similar to those
previously shown to be associated with Aβ levels [31].
Normative data from the Cache County study was used
to developthe standardized cut-oﬀ scores utilized in ADAPT
[32]. Individuals who scored below the cut scores on annual
cognitive assessments underwent further dementia workup
including physical and neurological examinations, labora-
tory studies (i.e., CBC, chemistry count, sedimentation rate,
vitamin B12 and folic acid levels, thyroid test, and syphilis
serological test), and neuroimaging (i.e., MRI or CT),
as applicable. A more comprehensive neuropsychological
assessment was also administered by a neuropsychologist as
part of the dementia work-up. This battery of tests consisted
of the expanded Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) battery [33]; Logical Memory
I and II of the Wechsler Memory Scale-Revised [34]; Benton
Visual Retention Test [35] (Benton); a generative ﬂuency test
(animals); Control Oral Word Association Test (COWAT;
CFL) [36]; The Trail Making Test [37]; Symbol Digit
Modalities Test (SMDT) [38]; Shipley Vocabulary [39].
Following completion of all componentsof the dementia
work-up,aconsensusteamdeterminedcognitivestatususing
published diagnostic criteria. The annual battery was not
utilized in diagnostic determination. The diagnosis of AD
was made using NINCDS-ADRDA [40] and amnestic mild
cognitive impairment (MCI) using Petersen criteria [41].
All MCI patients were considered to be amnestic MCI,
as they only had memory impairment, but maintained
normal activities of daily living and overall had a well-
preserved cognition in other cognitive domains. AmpleInternational Journal of Alzheimer’s Disease 3
evidence indicates that amnestic MCI patients may be in a
transitional stage between normal aging and AD with 85%
of these subjects converting to AD over a 7-year period [42].
Additional evidence comes from an imaging study which
demonstrated that the pattern of brain atrophy in amnestic
MCI patients is typical of that observed in AD patients [43].
It is then reasonable to combine these diagnoses in a single
category, thus allowing a large enough numbers to supply
statistical power. Of the 215 subjects who gave blood for
the ancillary study, two developed non-AD dementia, and
another subject died with cognitive status unknown. Blood
Aβ values were unavailable for 4 subjects. Of the remaining
subject pool of 208 used in these analyses, 28 subjects met
criteria for either AD (n = 10) or MCI (n = 18) in the two
years following blood draw.
2.2. Sample Collection, Preparation, and Measurements.
Blood draws for Aβ measurement and APOE genotyping
were conducted by trained phlebotomists. Serum from
blood was prepared and processed using standard laboratory
procedures [16]. The serum Aβ content was determined,
as per manufacturer’s instructions, using the ELISA kits for
human Aβ1−40 and Aβ1−42 and the inter-assay CV, and the
intraassay CV was reported to be ≤10% (Invitrogen, Calif).
Additional details are provided elsewhere [16]. DNA was
extractedfromwholebloodforAPOEgenotypingusingPure
Gene Kits (Gentra systems, Calif), and APOE genotyping
was performed using previously established methods, as
described elsewhere [16]. APOE genotypes were unavailable
for 4 individuals, but these were included in the analyses.
2.3. Statistical Analyses. The data set was range checked, and
prior to analyses, the dependent and independent variables
were examined for missing data, outliers, and violations
of the normalcy assumption. Diﬀerences among groups on
demographic variables, neuropsychological variables, and
serum Aβ1−40 levels were examined using either the student’s
t-test or χ2 analyses, depending on the type of variable
measurement. The Mann-Whitney test was employed if
parametric assumptions were not met.
Time-updated Cox regression modeling was used to test
whether neuropsychological test scores, Aβ,o rac o m b i n a -
tion of both can predict conversion to MCI/AD in indi-
viduals who were cognitively normal at baseline. Potential
confounding variables shown to impact risk for cognitive
decline included age, education, gender, APOE status, serum
creatinine, triglycerides, presence of APOE ε4 allele, and
history of vascular disease as determined by treatment with
statins or antihypertensive medication which were entered as
covariates. The latter variables, coded dichotomously, have
been previously shown to impact Aβ levels [44]. Because
previous analyses revealed a nonsigniﬁcant increase of AD
risk with naproxen in this cohort [45], we also controlled for
this eﬀect.
Logistic regression modeling was employed to construct
receiver operator curves (ROC) to examine the predictive
performance of neuropsychological measures from the base-
line visit and serum Aβ levels in diagnoses of MCI/AD.
ROC curve comparisons were based on area under the curve
(AUC), SE, and the associated 95% conﬁdence interval (CI).
We subsequently calculated sensitivity of the various models
using the predicted probability of each subject by logistic
regression modelingwithspeciﬁcityofatleasteightypercent.
Post hoc power calculations using the G-power software for
multivariate regression analyses utilized here suggest a power
of nearly 100% at the alpha value 0.05 for the current sample
size, total number of predictors, and the observed eﬀect size.
All analyses were conducted using the SPSS version 16.0 for
Macintosh.
3.Results
The mean age and education of the sample was 76.7 (SD =
3.9) and 14.6 (SD = 2.8) years, respectively. The majority of
the sample was Caucasian (98.1%), and 51.9% were male.
Despite the cohort’s self-report of enriched family history,
less than one-third of the total sample (31.7%) carried at
least one APOE ε4 allele, a frequency similar to the general
population [44]. Comparisons on variables between subjects
who remained cognitively normal and those who declined
over the short follow-up period are reported in Table 1.
Although all subjects at enrollment performed within the
normal limits based on the established cut-oﬀ scores, those
that ultimately declined had generally poorer scores on the
3MS, MMSE, and all memory measures. The two groups
were also signiﬁcantly diﬀerent on serum Aβ1−42 levels and
Aβ1−42/Aβ1−40ratios prior to diagnoses of MCI/AD. Only
23% of the cognitively normal individuals had serum Aβ1−42
in the lowest quartile compared to the nearly 50% of the
diagnostic group (44% of MCI subjects and 50% of AD
subjects).
Time-dependent Cox regression analyses were per-
formed to examine the relationship between these cognitive
tests and Aβ on the prediction of subsequent conversion
to MCI/AD. All neuropsychological analyses were adjusted
for age, gender, and education, but no adjustment for the
study medications was required as these were baseline scores.
Cox regression analyses show that the model using neu-
ropsychological tests predicted MCI/AD (−2 log-likelihood
= 206.51, χ2 = 52.11, df = 8, P<. 001). Signiﬁcant individual
neuropsychological measures were 3MS (β = −0.25 ± 0.06,
Wald = 17.78, P<. 001); generative verbal ﬂuency (β =
0.12± 0.04, Wald = 8.09, P<. 004); HVLT-R scores (β =
0.24± 0.11, Wald = 4.58 P<. 032).
Cox regression analysis showed that Aβ1−42 measured in
the lowest twoquartilescompared to thehighest quartile was
a signiﬁcant individual predictor of conversion to MCI/AD
in this model (−2 log-likelihood = 197.47, χ2 = 38.41,
df = 15, P<. 001). The regression analysis utilizing the
Aβ1−42/Aβ1−40 ratio found similarly signiﬁcant results (−2
log-likelihood = 204.69, χ2 = 36.10, df = 14, P<. 001)
with the lowest ratios being most predictive of subsequent
conversion to MCI/AD. The ﬁnal full model, adjusting for
confound and the study medications, included HVLT-R,
ﬂuency, 3MS, Aβ1−42 levels, and Aβ1−42 quartiles (−2 log-
likelihood = 166.25, χ2 = 74.55, df = 18, P<. 001) with4 International Journal of Alzheimer’s Disease
Table 1: Variable comparisons between groups.
Variable MCI/AD (n = 28) Controls (n = 190)
Age 77.8 ±(3.9) years 76.6 ±(3.9) years
Education 14.61 ±(3.2) years 14.63 ±(2.8) years
% Male 67.9% 49.4%
%A P O Eε 4 carrier 42.3% 32.4%
Means ± SD
3MS 92.93 ± (4.0)
∗ 96.7 ± (3.0)
MMSE 28.29 ± (2.1)
∗ 28.98 ± (1.3)
HVLT-R 8.11 ± (2.1)
∗ 9.85 ± (2.0)
Digit Span:
Forward Score 8.36 ± (2.3) 8.27 ± (2.0)
Backward Score 6.93 ± (2.1) 6.87 ± (1.9)
Generative Fluency 24.86 ± (5.8) 25.66 ± (6.2)
RBMT 57.14 (25.4)
∗ 75.00 ± (31.2)
BVMT-R 6.46 ± (2.6)
∗ 8.07 ± (2.4)
Aβ1−40 138.08 ± (43.72) 146.24 ± (55.37)
Median (25th, 75th quartile)
Aβ1−42 7.23 (1.97, 17.49)
∗∗ 12.38 (6.28, 23.20)
Aβ1−42/Aβ1−40 ratio 0.05 (0.02, 0.10)
∗∗ 0.09 (0.05, 0.15)
∗t-Test P<. 05.
∗∗Mann-Whittney U P<. 05.
Note: 3MS = Modiﬁed Mini-Mental State Examination; MMSE = Mini-Mental State Examination; HVLT-R = Hopkin’s Verbal Learning Test-Revised, Trial 4;
RBMT = Rivermead Behavioral Memory Test; BVMT-R = Benton Visual Memory Test-Revised.
ﬂuency,3MS,andAβ1−42 inthelowesttwoquartilesassignif-
icant individual predictors of MCI/AD in the model. Aβ1−40
was not a signiﬁcant individual predictor. Similar results
were observed when Aβ1−40 levels and Aβ1−42 quartiles were
substituted in this model with Aβ1−42/Aβ1−40 ratios (−2 log-
likelihood = 168.49, χ2 = 72.90, df = 17, P<. 001).
Baseline values for the 3MS, HVLT-R, and generative
verbal ﬂuency scores were subtracted from those obtained at
the 12-month repeat testing to determine if changes in these
measuresdiﬀerbyAβ1−42 andAβ1−42/Aβ1−40 ratios.Inunad-
justed analyses, among subjects who converted to MCI/AD,
the greatest decline for HVLT-R was observed among indi-
vidualswiththelowestquartileofAβ1−42 (−1.17,± 2.33 SD)
and Aβ1−42/Aβ1−40 ratios (−0.75,±2.63 SD) where individ-
uals in the highest quartile of Aβ1−42 (1.33,± 1.86 SD) and
Aβ1−42/Aβ1−40 ratios improved by nearly one point (0.6 ±
1.82 SD). However, these diﬀerences were not statistically
signiﬁcant (P>. 05). For the 3MS scores, among subjects
who converted to MCI/AD, those with Aβ1−42 in the lowest
quartile declined (−1.83 ± 1.28 SD) as compared to the
highest quartile (4.83 ± 1.35 SD), and this diﬀerence was
statistically signiﬁcant (F = 3.42, P = .033). For MCI/AD
subjects with the lowest quartile of the Aβ1−42/Aβ1−40 ratios,
the 3MS values remained ultimately unchanged (0.16 ±
1.20 SD), while the scores improved among those with the
highest quartile of the Aβ1−42/Aβ1−40 ratios (4.33±1.20 SD),
and these diﬀerences were also statistically signiﬁcant (F =
3.10, P = .046). For generative verbal ﬂuency test, a decline
was noted in both the lowest quartile (−4.17 ± 1.40 SD)
and the highest quartile (−1.17 ± 2.13 SD) of Aβ1−42,a n d
these diﬀerences were marginally signiﬁcant (F = 2.63,
P = .073). For Aβ1−42/Aβ1−40 ratios, a similar pattern was
observed, but this diﬀerence was not statistically signiﬁcant.
Among individuals who remained cognitively normal, while
a similar pattern was observed, those with lowest quartile of
Aβ1−42 and Aβ1−42/Aβ1−40 ratios had a larger decline than
those with the highest quartile for each HVLT-R (−0.28 ±
0.27 SD versus. 0.14 ± 0.33 SD, respectively.) and 3MS
(−1.02 ± 0.51 SD versus −0.39 ± 0.44 SD). However, due
to the small magnitude of the change in these scores, these
diﬀerences were not statistically signiﬁcant. No such change
was observed for the generative verbal ﬂuency test (data not
shown).
Examination of sensitivity and speciﬁcity using ROC
analysis revealed the AUC for neuropsychological testing
with age, education, and gender as covariates was 0.83 (95%
CI [0.75–0.91], P<. 001). For Aβ1−42 (adjusted for presence
of APOE ε4 allele, vascular risk factors, and associated
medications), the AUC was 0.79 (95% CI [0.70–0.88], P<
.001). When neuropsychological testing (3MS, HVLT-R, and
Generative Verbal Fluency) and Aβ1−42 were combined, the
AUC was increased to 0.91 (95% CI [0.86–0.95], P<. 001).
For the adjusted (as above) Aβ1−42/Aβ1−40 ratios alone,
the AUC was 0.79 (95% CI [0.71–0.88], P<. 001), and
when combinedwith theneuropsychologicalmeasures, AUC
was 0.91 (95%CI [0.87–0.96], P<. 001). The various
ROC curves are displayed in Figure 1. Optimal sensitivities
with speciﬁcity of at least 80% predicted probabilities are
shown in Table 2. The highest sensitivity and speciﬁcity
was achieved using a combination of cognitive scores and
Aβ1−42/Aβ1−40 ratio, but this ﬁnding was driven by Aβ1−42.International Journal of Alzheimer’s Disease 5
Table 2: Optimal sensitivities with speciﬁcities at least 80% for the various models∗.
Model Sensitivity Speciﬁcity  R2
￿Goodness-of-ﬁt test
Neuropsychological tests† 67.9% 80.0% 0.32 9.32
Aβ1−40 and Aβ1−42 55.6% 80.0% 0.22 12.81
Aβ1−42/Aβ1−40 ratio 59.3% 80.0% 0.22 6.28
Neuropsychological tests and Aβ1−40 and Aβ1−42 85.2% 85.9% 0.47 2.31
Neuropsychological tests and Aβ1−42/Aβ1−40 ratio 85.2% 86.5% 0.49 4.48
∗Calculationsbased on predicted probabilities form Logistic Regression.
†Modiﬁed Mini-Mental State Examination, Hopkins Verbal Learning Test-Revised Trial 4, supermarket ﬂuency.
 Represents Negelkerke R2.
￿Hosmer and Lemeshow chi-square test of goodness of ﬁt, a P value of >. 05 was noted and indicates that the model adequately ﬁts the data.
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4.Discussion
The pathogenesis of AD is initiated before the clinical
symptoms of cognitive impairment and functional decline
become apparent in its victims. A simple and pragmatic
method for identifying older adults at an increased risk
for MCI/AD who may beneﬁt from targeted prevention
is therefore of importance in reducing the burden of AD.
The combination of brief neuropsychological tests along
with blood-based biomarkers of AD represents a reasonable
approach with a potential for wide-scale use. Our ﬁndings
here provide support for this notion and demonstrate that
early prediction of risk for developing MCI/AD may be
feasible via a combination of brief neuropsychological tests
a n db i o m a r k e r si na na t - r i s kc o h o r t .I nt h i ss u b c o h o r t
from ADAPT, measures of global cognitive function (3MS),
episodic memory (HVLT-R Trial 4), language ﬂuency, and
serum Aβ1−42/Aβ1−40 ratio achieved an excellent accuracy of
91%. Furthermore, sensitivity with speciﬁcity of at least 80%
for the combined measures was superior to neuropsycholog-
ical measures or to serum Aβ levels alone.
We have recently shown that Aβ levels alone can predict
MCI/AD [14], but Aβ levels are inﬂuenced by vascular dis-
ease and associated medications [44] and require adjustment
to observe the full impact of Aβ in predictive modeling.
We have also shown that in subjects diagnosed with AD,
there is an association between measures of language tests
of ﬂuency and object naming and Aβ1−40 and that mem-
ory performance is associated with serum Aβ1−42[31]. An
association between serum Aβ1−40 and cognitive measures of
memory and language has also been reported in cognitively
normal older adults [46]. High baseline Aβ1−42 and Aβ1−40
with stable Aβ1−42 over time is shown to be associated
with diminishing cognition [47]. More recently, Yaﬀea n d
colleagues demonstrated that low Aβ1−42/Aβ1−40 ratios pre-
dict cognitive decline over 9 years [48]. In our study, we
demonstrate that low Aβ1−42 and Aβ1−42/Aβ1−40 ratios are
associated with cognitive decline even within one year. This
is extremely valuable from the clinical perspective, as the
ability to identify at-risk individuals within a year prior to
the onset can signiﬁcantly improve the quality of care and
the recruitment strategy for prevention trials by redirecting
those individuals who may not beneﬁt from preventive
therapies towards more suitable clinical intervention. This
is demonstrated by recent ADAPT ﬁndings, which suggest
that individuals with low baseline cognitive scores converted
soon after the trial initiated and that neither naproxen nor
celecoxib intervention was beneﬁcial to these individuals
[49]. Collectively, these ﬁndings suggest that combining
cognitive tests with blood Aβ may be useful for predicting
future MCI/AD, which to date has not been explored,
particularly as either Aβ or the cognitive tests alone may not
have the desired sensitivity or speciﬁcity for prediction of
future MCI/AD.
This current work presented here provides evidence
that the combination of brief neuropsychological tests and
blood Aβ has potential utility in predicting MCI/AD at
least 2 to 4 years prior to the clinical classiﬁcation of
MCI or diagnosis of AD. In addition, our ﬁndings also
demonstrate the importance of accounting for factors such
as APOE, vascular risk factors, and medications when using
Aβ in predicting MCI/AD. Although at present no studies6 International Journal of Alzheimer’s Disease
have reported sensitivity and speciﬁcity of CSF Aβ1−42 in
predicting MCI/AD conversion from normal cognition, a
large multicenter study has shown that CSF Aβ1−42 predicts
transition from MCI to AD [50], while tau alone achieved
a high sensitivity (83%) with acceptable speciﬁcity (72%).
It is interesting to note that our ﬁndings using blood
and cognitive tests, a far less invasive method, resulted in
higher sensitivities and speciﬁcities for predicting cognitive
decline in at-risk cognitively normal older adults. Despite
the limitation that blood sampling was not conducted at the
same time point as the cognitive testing, our data provide
strong support for further evaluation of this approach,
particularly as we have not seen signiﬁcant ﬂuctuations in
Aβ levels over a one-year period (pers. Comm.).
5.Conclusion
Our study provides support that blood-based Aβ levels
may have diagnostic utility when combined with neu-
ropsychological measures. This proposed method warrants
further investigation to determine its practical applicability
in specialized clinic setting by allied health personal and in
routine primary care clinics.
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